Argenx Halts Phase 3 Thyroid Eye Disease Trial: Clinical Setback With Focused Market Impact

Argenx (ARGX) announced an update on their ongoing clinical study.

Argenx Ends Key Thyroid Eye Disease Trial: What Investors Need to Know

The phase 3 study “A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants With Thyroid Eye Disease” tested efgartigimod PH20 SC in adults with active, moderate-to-severe thyroid eye disease. It aimed to show whether the drug could safely improve eye symptoms versus placebo and support a new market opportunity in an area with high unmet need.

The treatment under review was efgartigimod PH20 SC, a subcutaneous combination product given by prefilled syringe. It was compared with a matching placebo injection, with the goal of reducing disease activity and improving eye function and appearance for patients.

The trial used a randomized design, so participants were assigned to efgartigimod or placebo in a 2:1 ratio by chance. It was double-masked for patients, doctors, study staff, and outcome assessors, meaning no one knew who received active drug or placebo, and the main goal was to test the treatment effect in a real-world like setting.

The study was first submitted on 6 March 2024, marking formal launch of this phase 3 effort in thyroid eye disease. A key update came on 13 March 2026, when the registry was last updated to reflect early termination after a pre-defined interim analysis showed the trial was unlikely to meet its efficacy goals.

The trial was officially terminated on 15 December 2025, and only safety follow-up and end-of-study visits now remain. No primary completion or final completion dates are listed because the study stopped early once the interim review suggested limited benefit, though the company noted no new safety concerns.

For investors, the setback reduces near-term optionality for Argenx (ARGX) in thyroid eye disease and may trim long-term revenue expectations tied to this indication. The company’s core efgartigimod franchise in other autoimmune diseases remains intact, but the news could pressure sentiment as investors reassess the breadth of the pipeline versus competitors with successful thyroid eye disease drugs, such as Horizon’s Tepezza now under Amgen.

The termination underscores clinical risk in autoimmune ophthalmology and may shift capital toward companies with later-stage or already approved assets in this niche. The study is now terminated with follow-up ongoing and further details are available on the ClinicalTrials.gov portal.

To learn more about ARGX’s potential, visit the Argenx drug pipeline page.